1116
PAPER
A randomised pilot study to assess the efficacy of an
interactive, multimedia tool of cognitive stimulation
in Alzheimer’s disease
LTa´rraga,MBoada,GModinos,AEspinosa,SDiego,AMorera,MGuitart,JBalcells,
O L Lo´pez, J T Becker
...............................................................................................................................
JNeurolNeurosurgPsychiatry2006;77:1116–1121.doi:10.1136/jnnp.2005.086074
Objective: To determine the usefulness of an interactive multimedia internet-based system (IMIS) for the
cognitivestimulationofAlzheimer’sdisease.
Seeendofarticlefor
authors’affiliations Methods: This is a 24-week, single-blind, randomised pilot study conducted on 46 mildly impaired
....................... patientssuspectedofhavingAlzheimer’sdiseasereceivingstabletreatmentwithcholinesteraseinhibitors
(ChEIs).Thepatientsweredividedintothreegroups:(1)thosewhoreceived3weekly,20-minsessionsof
Correspondenceto:
LTa´rraga,Fundacio´ACE, IMISinadditionto8h/dayofanintegratedpsychostimulationprogram(IPP);(2)thosewhoreceivedonly
InstitutCatala` de IPP sessions; and (3) those who received only ChEI treatment. The primary outcome measure was the
Neurocie`nciesAplicades,
Alzheimer’sDiseaseAssessmentScale-Cognitive(ADAS-Cog).Secondaryoutcomemeasureswere:Mini-
Marque`sdeSentmenat,
35-37,08014Barcelona, Mental State Examination (MMSE), Syndrom Kurztest, Boston Naming Test, Verbal Fluency, and the
Spain; RivermeadBehavioralMemoryTeststoryrecallsubtest.
ltarraga@fundacioace. Results:After12weeks,thepatientstreatedwithbothIMISandIPPhadimprovedoutcomescoresonthe
com
ADAS-CogandMMSE,whichwasmaintainedthrough24weeksoffollow-up.Thepatientstreatedwith
Received9December2005 IPP alone had better outcome than those treated with ChEIs alone, but the effects were attenuated after
Revisedversionreceived 24weeks.All patients had improvedscores inall of theIMISindividual tasks,attaining higherlevels of
15June2006 difficultyinallcases.
Accepted20June2006
Conclusion:AlthoughboththeIPPandIMISimprovedcognitioninpatientswithAlzheimer’sdisease,the
PublishedOnlineFirst
4July2006 IMIS program provided an improvement above and beyond that seen with IPP alone, which lasted for
....................... 24weeks.
lzheimer’s disease is the most frequent form of Despitetheprogressivenatureofthedegenerativeprocess,
A
dementiainelderlypeople,12anditscurrenttreatment patients with Alzheimer’s disease also seem to retain the
includes cholinesterase inhibitors (ChEIs),3–5 and N- physiological capacity to alter brain structure and function.
methyl-D-aspartate receptor blockers (eg, memantine).6 Recent studies have shown cognitive plasticity and learning
However,symptomatictreatmentoftenentailsnon-pharma- potential not only in patients with Alzheimer’s disease but
cologicaltreatmentsaswell,andadequatedementiamanage- also in healthy elders.2223 Positron emission tomography
mentrequiresawiderangeofinterventiontohelpmaximise studies that used activation paradigms2425 have found that
the patient’s independence, increase their self-confidence people with Alzheimer’s disease have a greater activation
andrelieveburdentothecaregiver. than those without dementia in the brain regions usually
CurrentsymptomatictreatmentofAlzheimer’sdiseasecan associatedwithmemorytasks,aswellasinthefrontallobes
improve cognition and functionality.3–6 However, before the that were activated only with increasing difficulty of tasks.
emergence of these drugs, non-pharmacological treatments Pathological studies conducted on biopsy specimens of
had already been evaluated and cognitive stimulation had patients with Alzheimer’s disease with mild or moderate
been found to be potentially beneficial for patients with dementiahaveshownincreasedsynapticcontactsize.26Thus,
dementia.7–9Althoughthesenon-pharmacologicaltreatments thebrainmaybeabletocompensateduringtheearlystages
do not always seem efficacious, methodological problems of Alzheimer’s disease, suggesting that there may be some
may limit the validity of some studies.10 A recent Cochrane
utilitytonon-pharmacologicaladjunctiveinterventions.
review11emphasisedcautionwheninterpretingtheresultsof
Although studies on cognitive stimulation show that it is
non-pharmacological treatments, but suggested that certain
possibletostimulatethememoryofpatientswithAlzheimer’s
cognitivedomainscould,infact,benefitfromthesetypesof
disease, the results are often modest. Because of methodolo-
interventions.
gicallimitations,thereisaneedtoconductmorerandomised-
Clinical and laboratory studies have shown that mental
controlledtrialswithlargersamplestovalidatethistherapeutic
and physical activity can positively influence cognition in
approach.Computerisedsystems27andinternet-baseddistance
normalelderlypeopleandpeoplewithdementia.Education12
programs offer one potential mechanism by which non-
andlifestylechoices(eg,occupationandleisureactivities)13–15
pharmacological cognitive stimulation can be conducted in
can modulate the risk of developing dementia, and psycho-
motor stimulation improves cognition in patients with
Alzheimer’s disease.1617 Environmental enrichment can Abbreviations: ADAS-Cog,Alzheimer’sDiseaseAssessmentScale-
Cognitive;BNT,BostonNamingTest;ChEIs,cholinesteraseinhibitors;
improve cognition in transgenic mice.1819 Despite the
GDS,GlobalDeteriorationScale;IMIS,interactivemultimediainternet-
continued deposition of b-amyloid, exercise can increase
basedsystem;IPP,integratedpsychostimulationprogram;MMSE,Mini-
the levels of brain-derived neurotrophic factor20 and may MentalStateExamination;RBMT,RivermeadBehavioralMemoryTest;
reduceamyloidburden.21 SKT,SyndromKurztest
www.jnnp.com
MultimediatoolofcognitivestimulationinAlzheimer’s disease 1117
N
patients with dementia. In this study, we evaluated an Experimentalgroup:Thesepatients receivedthe IMIS,as
interactive multimedia internet-based system (IMIS) as an wellastheIPPandChEIs.
N
adjunct to ChEI treatment and classic psychostimulation IPPcontrol:ThesepatientsreceivedIPPandChEIs.
N
treatment.
ChEIscontrol:ThesepatientsreceivedonlyChEIs.
The ChEIs group comprised of patients who were
MATERIALS AND METHODS
diagnosed with Alzheimer’s disease, but who were living at
Forty six patients suspected of having Alzheimer’s disease28
home,andneverreceivedtheIPPortheIMIS.Thesepatients
were recruited for the study through a referral clinic and
eitherdidnotwanttocometothedaycarecentre,although
daycare centre (Fundacio´ ACE, Institut Catala` de
theyagreetobefollowedclinically,orwereonawaitinglist
Neuroci`encies Aplicades, Barcelona, Spain). The Institut
for admission to the daycare centre. The experimental and
Catal`a de Neurocie`ncies Aplicades is a referral diagnostic
the IPP control groups were participants in the daycare
clinic for community-dwelling people with dementia, and
centre,andtheonlydifferencebetweenthesetwogroupswas
also provides adult daycare services to these patients. All of
that the experiment group received the IMIS. Written
the patients had been treated with ChEIs for at least 1year
informed consent was obtained from all the participants
beforeinclusiontothestudy.Theinclusioncriteriawere:
enrolledinthestudyandtheirlegalrepresentativebeforethe
N
studyonset.
.65yearsofage;
N Three patients in the experimental group dropped out of
atleast3yearsofeducation;
N thestudy:onebecauseofrapidprogressionofthediseaseand
a Mini-Mental State Examination (MMSE)2930 score two because of institutionalisation. Consequently, from the
N between18and24; initial sample of 46, 43 patients completed the study: 15 in
aGlobalDeteriorationScale(GDS)31scoreof3or4; theexperimentalgroup,16intheIPPcontrolgroupand12in
N
absenceofuncontrolleddisruptivebehaviours(eg,aggres- theChEIcontrolgroup(table1).
sion, delusions, hallucinations and agitation) that could
interfere with program administration and/or neuro- Experimental group
psychologicalassessments; ThesepatientsreceivedtheIMIS,IPPandChEIs.
N
absenceofmajordepression,currentorpartialremission32;
N
IPP control
absenceofstructurallesionsinthecomputedtomogramor
ThesepatientsreceivedIPPandChEIs.
magneticresonanceimage;
N
absenceofhistoryofalcoholorothersubstanceabuse;and
N ChEI control
absence of severe auditory, visual or motor deficits that ThesepatientsreceivedonlyChEIs.
mayinterferewithcognitivetesting. No significant differences were observed between the
groups in terms of age (F =0.72) or level of education
2,41
None of the participants had previous experience with a (x2=5.513, df=4, p=0.239). There was a tendency for a
personal computer and all attended the daycare centre difference in the proportion of male patients, primarily
5days/week.Participantswereallowedtobeonstabledoses because all the patients in the ChEI group were female;
ofpsychotropicdrugs. however,thedifferencewasnotsignificant(x2=5.70,df=2,
p=0.06).
Multimedia treatment Patients were assessed at study entry, and after 12 and
The IMIS was conducted using Smartbrain (http://www. 24weeks of treatment. The primary outcome measure was
educamigos.com),aninteractivemultimediatoolthatallows theAlzheimer’sDiseaseAssessmentScale-Cognitive(ADAS-
patients to carry out a variety of different stimulation Cog) section.33 This is a standardised measure of cognitive
programs, at different levels of difficulty and at various function that examines components of memory, language,
timesduringtheday.Briefly,theIMISprogramconsistsof19 visuoconstructional and ideational praxis, and orientation.
separate‘‘tasks’’orstimulationexercisesacrossthedomains High ADAS-Cog scores indicate worse performance. The
of attention, calculation, gnosis, language, memory and secondarymeasureswere:
N
orientation. All participants began at the lowest level of
MMSE:Thisisaglobalmeasureofcognitivefunctionthat
difficulty (first of 15 levels) and the program monitored
examines orientation to time and place, immediate and
activityateachlevel.Difficultyincreasedautomaticallyafter
delayed recall of three words, attention and calculation,
threeconsecutiveperformanceswithinasingletaskwithout
languageandvisuoconstructionalfunctions.
error,orwhenapatientwas80%correctoversixconsecutive N
Syndrom Kurztest (SKT)34: This is a short cognitive perfor-
sessions.Apatient’slevelofdifficultydecreasedwhenhisor
mance test that examines memory and attentional
herperformancefellbelow15%correctforthreeconsecutive
functions.
sessions or ,20% correct for six consecutive sessions. All N
patients were trained before the study with the use of the Boston Naming Test (BNT)35: Patients must name 60 large
inkdrawingsthatarepresentedtothembytheexaminer.
computermouse,especiallyonhowto‘‘clickanddrag’’.
Integrated psychostimulation program Table1 Demographiccharacteristicsofthepatients
TheIPPisadailyprograminthedaycarecentrethatincludes
Experimental IPPcontrol ChEIcontrol
cognitive stimulation tasks, workshops (eg, music therapy,
group group group
art and crafts, and physical activity) and reinforcement of
instrumentalactivitiesofdailyliving.17TheIPPisintegrated Patients 15 16 12
Male/female 5/13 2/14 0/12
into the daycare centre activities, and it takes 2h in the
Meanage 75.8(5.9) 77.4(4.7) 76.9(4.5)
morning and 1.5h in the afternoon out of the 8h that the (SD)
patientsspendinthecentre.
Eachpatientwasrandomlyassignedtooneofthreestudy ChEI,cholinesteraseinhibitor;IPP,integratedpsychostimulation
program.
groups:
www.jnnp.com
1118 Ta´rraga,Boada,Modinos,etal
The test is discontinued after eight consecutive failures. differed from each other on the MMSE (D-lysergic acid
Whenthepatientfailstonamethedrawing,theexaminer diethylamidetest,p,0.05).After24weeks,groupdifferences
provides a semantic cue; if still unable to name the were still apparent on the ADAS-Cog (F =3.08, p=0.06,
2,42
drawing,aphonemiccueisprovided. r=0.36) and MMSE (F =8.48, p=001, r=0.54).
N 2,42
Verbalfluency:Thisincludeslettergeneration(letterP)and Reanalyses showed that the experimental group was better
animalfluencytests. than the ChEI control group on the ADAS-Cog (p,0.05),
N
whereas the experimental and IPP control groups differed
The story recall subtest from the Rivermead Behavioral Memory
fromtheChEIscontrolgroupontheMMSE(p,0.05;fig2).
Test(RBMT)36:Patientslistentoashortpassageofaprose
TherewasnosignificantchangeinSKTscoresover24weeks
beingreadaloudandthenrecallasmuchastheycan.
N across all three groups (F =0.83), and no significant
Rapid Disability Rating Scale—2 (RDRS-2)37: This is an 2,39
groupbytimeinteraction(F =1.93,p=0.11,r=0.30).
assessment of three functional and behavioural areas: 2,39
Measuresatweek12and24areshownascomparedwith
(a) help with activities of daily living, (b) degree of
baseline(table3).
disability, and (c) degree of special problems (ie, mental
Nosignificantdifferenceswereobservedinthefunctional
confusion,uncooperativenessanddepression).TheRDRS-2
assessments, as measured by the RDRS-2 at baseline
was administered at baseline and at 24-week follow-up
examination (experimental group mean: 26.6 (SD 0.96),
examination.
N IPPcontrol:27.3(0.93),ChEIcontrol:24.4(1.0);F =2.16,
2,42
GDS31: This is a staging system of seven distinguishable p=0.12, r=0.32), or after 24weeks of follow-up (experi-
cognitive and functional stages, ranging from normal mental group: 25.3 (1.1), IPP control: 25.6 (1.0), ChEI
(stage0)toseveredementia(stage7).Allpatientsinthe control:23.7(1.2);F =0.76,p= 0.47,r=0.14).TheGDS
2,42
studyhadaGDSstage4. stage was 4 in all patients at baseline and in all follow-up
evaluations.
The primary and secondary outcome measures were
Figure 3 shows the mean difficulty level obtained by the
administeredtoallparticipantsintheexperimentalandIPP
patientsoverthecourseofthe24weeksoftreatmentineach
control groups at all visits. Owing to manpower limitations,
ofthesixcognitivedomainsoftheIMIS.Performanceinall
the BNT, verbal fluency tests and RBMT (all secondary
cognitive domains showed an improvement, but most
outcome measures) were not administered to the ChEI
especially in the measures of attention and memory. In no
controlgroupatanyvisit.
case did a patient’s performance level for any individual
activityactuallydeclineoverthecourseofthe24weeks.
INTERACTIVE MULTIMEDIA INTERVENTION
Patientsintheexperimentalgroupreceivedatotalof72IMIS
DISCUSSION
sessions,threetimesaweekfor24weeks.Allofthepatients
This study shows that both classic cognitive stimulation
in the experimental group had the same computerised
treatmentandcomputer-basedtreatmentimprovedcognition
activities, order of presentation and session length. During
in patients who were treated with a stable dose of ChEI,
the first 24 sessions, the IMIS sessions lasted only 15min.
compared with those who were treated only with ChEIs. In
Sessions 25–28 lasted 20min, and sessions 29–72 lasted
addition,theIMISprogramprovidedanimprovementabove
25min. Because this was the first time that such a
andbeyondthatseenwithclassiccognitivestimulation,with
computerised multimedia program was applied for the
improvementlasting24weeks.NotonlydidADAS-Cogand
cognitive stimulation of these patients, it was necessary to
MMSEscoresfailtodecline(aswasseenintheChEIscontrol
ensure tolerability and adequate dose to avoid fatigue or
group) but scores also actually improved, and the improve-
otherpossiblenegativeeffectsthatmightarisefromexposure
ment was maintained over the 24weeks that the IMIS was
to a PC. A minimum requirement was that the participants
partofthetreatmentprogramme.
completed58of72(80%)sessions,withaninterruptionofno
The progression of illness observed in the ChEI control
morethan10daysbetweensessions;allparticipantsmetthis
groupisconsistentwithwhathaspreviouslybeendescribed
criterion.
insubjectswithprolongedexposuretoChEIs(.1year).38On
average, this group declined at a rate of approximately 2–3
STATISTICAL ANALYSIS MMSE points per year, which is slightly slower than is
The data were analysed using SPSS V.12. Descriptive
typical,butfallswithintherangeofexpecteddeclineinmild
statisticswerepreparedatbaseline,12weeksand24weeks.
Alzheimer’sdisease.39
Outcomeswere assessed using one-way analysisofvariance
Theseresultsshowthatitispossibletoaugmenttheeffects
ateachofthethreecriticaltimepoints.
of cholinesterase inhibition using cognitive stimulation
procedures, with the result that patients have improved
RESULTS outcomes. These findings from the experimental group
Table1showsthecharacteristicsofthegroups. cannot be explained simply by increased social contact or
Nosignificantdifferenceswereobservedbetweenthethree interactions, as the experimental group and the IPP control
study groups on the ADAS-Cog (F =0.67) or SKT group attended the daycare centre. The IMIS greatly
2,42
(F =0.84) at baseline, although the experimental group augmentedthetraditionalpsychomotorstimulation,because
2,42
had slightly lower MMSE scores than the other groups when both treatments were used together efficacy was
(F =3.33, p=0.046; table 2). There were no differences extended to 24weeks. Thus, it seems that an individually
2,42
betweentheexperimentalandtheIPPcontrolgroupsonthe constrainedcognitivestimulationprogramsuchastheIMIS
other neuropsychological measures at baseline examination usedhereismoreefficaciousthantreatmentonlywithdrugs,
(theChEIcontrolgroupdidnotreceivetheseadditionalfour and at least augments traditional psychostimulation. In
tests;table2). regard to the possible effects of IMIS-alone treatment, we
After 12weeks of treatment, the three study groups hypothesise that it would represent an improvement com-
differed in terms of the ADAS-Cog (F =7.05, p=0.002, pared with non-treated patients and also with patients
2,42
r=0.50) and the MMSE (F =10.3, p,0.001, r=0.57; treatedwithChEIsalone,asshowninpreviousstudies.2740
2,42
fig 1). Both experimental and IPP control groups were The degree of difficulty of the problems is individually
superior to the ChEI control group on the ADAS-Cog (D- adjusted to maximise success (and increase the challenges)
lysergicaciddiethylamidetest,p,0.05),andallthreegroups for each patient. Although an understanding of the
www.jnnp.com
MultimediatoolofcognitivestimulationinAlzheimer’s disease 1119
Table2 Neuropsychologicalcharacteristicsatbaseline,andat12and24weeksfollow-upexamination
Test Assessment Experimentalgroup IPPcontrolgroup ChEIcontrolgroup
Baseline 20.60(2.10) 22.50(2.90) 22.83(2.37)
MMSE Week12 22.53(2.56) 23.00(3.41) 21.75(2.26)
Week24 22.07(3.03) 22.63(3.79) 21.33(2.23)
Baseline 22.40(5.70) 21.19(5.73) 20.00(4.35)
ADAS-cog Week12 19.86(4.78) 18.75(4.40) 21.08(4.52)
Week24 21.33(5.74) 22.31(6.81) 21.83(4.48)
Baseline 11.80(3.88) 11.62(4.91) 13.83(5.72)
SKT Week12 12.00(3.78) 9.88(4.03) 14.58(5.25)
Week24 12.07(4.65) 10.81(5.10) 15.16(5.44)
Baseline 36.53(10.64) 36.31(7.04) —
BNT Week12 37.07(10.05) 38.63(7.04) —
Week24 37.20(10.26) 37.25(8.21) —
Baseline 10.67(3.64) 8.31(3.14) —
Semanticfluency Week12 10.93(3.04) 9.13(3.63) —
Week24 9.60(4.41) 8.75(4.07) —
Baseline 9.53(3.93) 8.19(3.54) —
Phoneticfluency Week12 9.00(3.98) 7.94(3.89) —
Week24 9.20(3.53) 8.19(4.09) —
Baseline 1.73(1.03) 2.13(1.46) —
Storyrecallsubtest
Week12 2.20(1.37) 2.25(1.69) —
(RBMT)
Week24 2.13(1.55) 2.25(1.48) —
ADAS-Cog,Alzheimer’sDiseaseAssessmentScale-Cognitive;BNT,BostonNamingTest;ChEI,cholinesteraseinhibitor;IPP,integratedpsychostimulation
program;MMSE,Mini-MentalStateExamination;RBMT,RivermeadBehavioralMemoryTest;SKT,SyndromKurztest.
physiological basis of the efficacy of these individualised other cognitive functions43 or activities of daily living
cognitive stimulation programs is beyond the scope of this (ADLs)44;
N
initialstudy,ourfindingsanddatafromotherssuggestthat traininginADLs(proceduralmemorystimulation)andits
plasticity remains possible in patients with Alzheimer’s effectsonthesametasks45;
N
disease at the cellular level, and that these changes can
psychosocialinterventionprogrammes(ie,realityorienta-
modifydisease progression.22–26 Cellular plasticity could thus
tiontreatment)46;
provide a substrate on which the improvements observed N
combination of cognitive stimulation and counselling
herecouldbebased.
(patientsandcaregivers)47;
No functional improvement was noted among the three N
groups. This may be explained by the fact that these were combination of cognitive rehabilitation with mental
mildly impaired patients (mean MMSE was 22.0), who N stimulationtechniques48;
retained the physical orfunctional abilityto participate in a combination of cognitive enhancers and computerised
cognitiveormotorstimulationprogram,anddidnotexhibit cognitivetraining49;and
N
disruptivebehaviours.Similarly,theChEIcontrolgroupwas comprehensive cognitive and motor stimulation pro-
only mildly impaired, and they had sufficient support from grammes.16
theircaregivertocometotheclinicforfrequentevaluations.
Therefore,anychangeinfunctionalcapacitycouldhavebeen Althoughtheseapproachesshowvaryingdegreeofbenefits
more difficult to measure in this cohort than in patients in from non-pharmacological interventions in patients with
moderate or severe stages of dementia. In addition, it is Alzheimer’s disease, it is difficult to establish comparisons
possiblethatthefunctionalmeasuresusedinthisstudywere amongstudies,astheoutcomemeasuresanddurationofthe
notsensitiveenoughtodetectsubtlechange. interventions were not the same, especially when compared
There have been multiple methodological approaches to with drug trials. Studies of non-pharmacological interven-
explore the benefits of non-pharmacological treatments in tionsshould,therefore,usethesameoutcomemeasuresand
patientswithAlzheimer’sdisease.Theseincludedstudiesof: study duration as the pharmacological trials to provide a
N better perspective of the effects of non-pharmacological
memorytraininginonespecifictask(eg,errorlesslearning treatments. This study used the ADAS-Cog and MMSE,
paradigm) and its effects on memory function,4142 or on which are the standard cognitive measures used in drug
trials; participants who had cognitive or motor stimulation
Figure1 Mini-MentalStateExaminationmeanchangeat12and Figure2 Alzheimer’sDiseaseAssessmentScale-Cognitivemean
24weeks.ChEI,cholinesteraseinhibitor;IPP,integrated changeafter12and24weeks.ChEI,cholinesteraseinhibitor;IPP,
psychostimulationprogram. integratedpsychostimulationprogram.
www.jnnp.com
1120 Ta´rraga,Boada,Modinos,etal
Table3 Meanchangeincognitivemeasuresat12and24weeksfollow-up
Test Assessment Experimentalgroup IPPcontrolgroup ChEIcontrolgroup
Baseline 0 0 0
MMSE Week12 1.93 0.50 21.08
Week24 1.47 0.13 21.50
Baseline 0 0 0
ADAS-Cog* Week12 22.54 22.44 1.08
Week24 21.07 1.12 1.83
Baseline 0 0 0
SKT* Week12 0.20 21.74 0.75
Week24 0.27 20.81 1.33
Baseline 0 0 —
BNT Week12 0.54 2.32 —
Week24 0.67 0.94 —
Baseline 0 0 —
Semanticfluency Week12 0.26 0.82 —
Week24 21.07 0.44 —
Baseline 0 0 —
Phoneticfluency Week12 0.53 20.25 —
Week24 0.33 0 —
Baseline 0 0 —
Storyrecallsubtest(RBMT) Week12 0.47 0.12 —
Week24 0.40 0.12 —
ADAS-Cog,Alzheimer’sDiseaseAssessmentScale-Cognitive;BNT,BostonNamingTest;ChEI,cholinesteraseinhibitor;IPP,integratedpsychostimulation
program;MMSE,Mini-MentalStateExamination;RBMT,RivermeadBehavioralMemoryTest;SKT,SyndromKurztest;0,baseline.
*Lowerscoresindicatecognitiveimprovement.
treatmenthadimprovedscores,andthiseffectwasenhanced Although this was a trial of a non-pharmacological
bytheuseofacomputerisedprogram. intervention, one way to conceptualise the design is to
Oneofthelimitationsofthestudyisthatwewereunable consider that we were able to evaluate ‘‘dose’’ and ‘‘toler-
to complete the neuropsychological battery (secondary out- ability’’. In this context, the ‘‘dose’’ refers to the amount of
comes) in the ChEI control group. Therefore, we could not time each day that a patient could engage in the IMIS.
further expand our analysis to specific cognitive domains. Similarly, we could consider the patient’s willingness to
The improvement seen with the ADAS-Cog and the MMSE complete the assigned tests on schedule as a measure of
was not seen with the SKT. This discrepancy could be ‘‘tolerability’’. Therefore, we started with sessions of 15min
explained by assessing whether these treatments have of duration and increased them to 25min, and all patients
beneficial effects in some cognitive domains, and not in completedtheminimumrequirementof58sessions.
others.However,thelimitedscopeofthecognitivefunctions Future research is needed to evaluate the efficacy of the
assessed by the SKT, and a possible ceiling effect in mildly IMIS-type programs in larger, more diverse populations to
impairedpatientscanalsoexplainthesefindings. understandfactorsthatmaymodifytheresponse,aswellas
The patients in the experimental and the IPP control toestablishitslong-termeffects(.1year).TheIMISshould
groups were in the daycare centre; the only difference be tested outside the controlled clinical environment (ie,
betweenthegroupswasthattheexperimentalgroupreceived home-based)todeterminetheefficacyof‘‘distancetherapy’’
inAlzheimer’sdisease.Nevertheless,theresultsofthisstudy
theIMIS.Patientsinthesegroupsweredrawnfromthesame
suggest that this is a promising avenue of approach to help
institution, where the IPP program is used in all patients.
maximise a patient’s cognitive functions in the context of a
Therefore, we could not create a group of patients receiving
progressive degenerative disease, potentially altering the
daycare only, as patients could not be isolated from their
effect of the condition on both the patients and the care
dailystimulationroutines(whichareanintegralpartofthe
givers.
daycareprogram).
ACKNOWLEDGEMENT
ThisstudywasconductedwithanunrestrictedgrantfromFundaci´o
ACE,InstitutCatal`adeNeuroci`enciesAplicades,Barcelona,Spain.
.....................
Authors’ affiliations
LTa´rraga,MBoada,GModinos,AEspinosa,SDiego,AMorera,
MGuitart,JBalcells,Fundacio´ACE.InstitutCatala` deNeurocie`ncies
Aplicades,Barcelona,Spain
OLLo´pez,JTBecker,DepartmentsofNeurologyandPsychiatry,
UniversityofPittsburghSchoolofMedicine,Pittsburgh,Pennsylvania,
USA
Competinginterests:Nonedeclared.
REFERENCES
1 OttA,BretelerMM,vanKarskampF,etal.Incidenceandriskofdementia.
TheRotterdamStudy.AmJEpidemiol1998;147:574–80.
2 FratiglioniL,LaunerLJ,KA,BretelerMM,etal.Incidenceofdementiaand
majorsubtypesinEurope:acollaborativestudyofpopulation-basedcohorts.
Neurology2000;54:S10–S15.
Figure3 Meanlevelsofdifficultyattainedbytheexperimentalgroup 3 RogersSL,FriedhoffLT.Theefficacyandsafetyofdonepezilinpatientswith
oneachcognitivefunctionovera24-weektrainingperiod. Alzheimer’sdisease:resultsofaUSmulticentre,randomized,double-blind,
www.jnnp.com
MultimediatoolofcognitivestimulationinAlzheimer’s disease 1121
placebo-controlledtrial.TheDonepezilStudyGroup.Dementia 27 HofmannM,HockC,KuhlerA,etal.Interactivecomputer-basedcognitive
1996;7:293–303. traininginpatientswithAlzheimer’sdisease.JPsychiatrRes
4 RoslerM,AnandR,Cicin-SainA,etal.Efficacyandsafetyofrivastigminein 1996;30:493–501.
patientswithAlzheimer’sdisease:internationalrandomisedcontrolledtrial. 28 McKhannG,DrachmanDA,FolsteinMF,etal.Clinicaldiagnosisof
BMJ1999;318:633–8. Alzheimer’sdisease:reportoftheNINCDS-ADRDAWorkGroupunderthe
5 RaskindMA,PeskindER,WesselT,etal.GalantamineinAD.Asix-month, auspicesoftheDepartmentofHealthandHumanServicesTaskForceon
randomized,placebo-controlledtrialwithasix-monthextension.Neurology Alzheimer’sdisease.Neurology1984;34:939–44.
2000;54:2261–8. 29 FolsteinMF,FolsteinSE,McHughPR.Mini-mentalstate:apracticalmethod
6 TariotPN,FarlowMR,GrossbergGT,etal.Memantinetreatmentinpatients gradingthecognitivestateofpatientsfortheclinician.PsychiatrRes
withmoderatetosevereAlzheimer’sdiseasealreadyreceivingdonepezil. 1975;12:189–98.
JAMA2004;291:317–24. 30 BlesaR,PujolM,AguilarM.Clinicalvalidityofthe‘‘mini-mentalstate’’for
7 BreuilV,DeRetrouJ,ForetteF.Cognitivestimulationofpatientswithdementia: Spanishspeakingcommunities.Neuropyschologia2001;39:1150–7.
preliminaryresults.IntJGeriatrPsychiatry1994;9:211–17. 31 ReisbergB,GordonB,McCarthyM,etal.Clinicalsymptomsaccompanying
8 WoodsRT.Non-pharmacologicaltechniques.In:QizilbashN,SchneiderLS, progressivecognitivedeclineandAlzheimer’sdisease.In:MelnickVL,
ChuiH,etal,eds.Evidence-baseddementiapractice.Oxford:Blackwell, DublerNN,eds.Alzheimer’sdementia.Clifton,NJ:HumanaPress,
2002:428–46. 1985:19–39.
9 DouglasS,JamesI,BallardC.Non-pharmacologicalinterventionsin 32 AmericanPsychiatricAssociation.DSM-IV:DiagnosticandStatisticManual
dementia.AdvPsychiatrTreat2004;10:171–9. ofMentalDisorders,4thedn.Washington,DC:AmericanPsychiatric
10 GrandmaisonE,SimardM.Acriticalreviewofmemorystimulationprograms Association,1994.
inAlzheimer’sdisease.JNeuropsychiatrClinNeurosci2003;15:130–44. 33 RosenWG,MohsRC,DavisKL.AnewratingscaleforAlzheimer’sdisease.
11 ClareL,WoodsRT,Moniz-CookED,etal.Cognitiverehabilitationand AmJPsychiatry1984;141:1356–64.
cognitivetrainingforearly-stageAlzheimer’sdiseaseandvasculardementia 34 ErzigkeitH.TheSKT:ashortcognitiveperformancetestasaninstrumentfor
[Review].CochraneDatabaseSystRev2003;4:CD003260. theassessmentofclinicalefficacyofcognitiveenhancers.In:BerengerM,
12 KatzmanR.EducationandtheprevalenceofdementiaandAlzheimer’s ReisbergB,eds.Diagnosisandtreatmentofseniledementia.Berlin:Springer
disease.Neurology1993;43:13–20. Verlag,1989:164–74.
13 VergheseJ,LiptonRB,KatzMJ,etal.Leisureactivitiesandtheriskof 35 GoodglassH,KaplanE,WeintraubS.In:Theassessmentofaphasiaand
dementiaintheelderly.NEnglJMed2003;348:2508–16. relateddisorders,2ndedn.Philadelphia:LeaandFebiger,1987.
14 WilsonRS,MendesdeLeo´nCF,BarnesLL.Participationincognitively 36 WilsonB,CockburnJ,BaddeleyA.TheRivermeadBehavioralMemoryTest.
stimulatingactivitiesandriskofincidentAlzheimer’sdisease.JAMA Reading:ThamesValleyTestCompany,1985.
2002;287:742–8. 37 LinnMW,LinnBS.Therapiddisabilityratingscale,part2.JAmGeriatrSoc
15 SternY,AlexanderGE,ProhovnikI,etal.Relationshipbetweenlifetime 1982;139:1136–9.
occupationandparietalflow:implicationsforareserveagainstAlzheimer’s 38 DoodyRS,GeldmacherDS,GordonB,etal.Open-label,multicenter,phase3
diseasepathology.Neurology1995;44:55–60. extensionstudyofthesafetyandefficacyofdonepezilinpatientswith
16 Olazara´nJ,Mun˜izR,ReisbergB,etal.Benefitsofcognitive-motor Alzheimerdisease.ArchNeurol2001;58:427–33.
interventioninMCIandmildtomoderateAlzheimerdisease.Neurology 39 DoodyRS,DunnJK,ClarkCM,etal.Chronicdonepeziltreatmentis
2004;63:2348–53. associatedwithslowedcognitivedeclineinAlzheimer’sdisease.Dement
17 Ta´rragaL.Softtherapies:theprogrammeofintegralpsychostimulation. GeriatrCognDisord2001;12:295–300.
AlternativetreatmentforpersonswithAlzheimer’sdisease.RevNeurol 40 HofmannM,RoslerA,SchwarzW,etal.Interactivecomputer-trainingasa
1998;27(Suppl1):S51–S62. therapeutictoolinAlzheimer’sdisease.ComprPsychiatry2003;44:213–19.
18 JankowskyJL,MelnikovaT,FadaleDJ,etal.Environmentalenrichment 41 ClareL,WilsonBA,RothI,etal.Relearningface-nameassociationsinearly
mitigatescognitivedeficitsinamousemodelofAlzheimer’sdisease. Alzheimer’sdisease.Neuropsychology2002;16:538–47.
JNeurosci2005;25:5217–24. 42 ClareL,WilsonBA,CarterG,etal.Cognitiverehabilitationasacomponentof
19 ArendashGW,Garc´ıaMF,CostaDA,etal.Environmentalenrichment earlyinterventioninAlzheimer’sdisease:asinglecasestudy.AgingMent
improvescognitioninagedAlzheimer’stransgenicmicedespitestablebeta- Health2003;7:5–6.
amyloiddeposition.NeuroReport2004;15:1751–4. 43 DavisRN,MassmanPJ,DoodyRS.CognitiveinterventioninAlzheimer
20 BerchtoldNC,ChinnG,ChouM,etal.Exerciseprimesamolecularmemory disease:arandomizedplacebo-controlledstudy.AlzheimerDisAssocDisord
forbrain-derivedneurotrophicfactorproteinindictionintherathippocampus. 2001;15:1–9.
Neuroscience2005;133:853–61. 44 Cahn-WeinerDA,MalloyPF,RebokGW,etal.Resultsofarandomized
21 AdlardPA,PerreauVM,PopV,etal.Voluntaryexercisedecreasesamyloid placebo-controlledstudyofmemorytrainingformildlyimpairedAlzheimer’s
loadinatransgenicmodelofAlzheimer’sdisease.JNeurosci diseasepatients.ApplNeuropsychol2003;10:215–23.
2005;25:4217–21. 45 ZanettiO,BinettiG,MagniE,etal.Proceduralmemorystimulationin
22 KempermanG,GastD,GageFH.Neuroplasticityinoldage:sustained Alzheimer’sdisease:impactoftrainingprogramme.ActaNeurolScand
fivefoldinductionofhippocampalneurogenesisbylong-termenvironmental 1997;95:152–7.
enrichment.AnnNeurol2002;52:135–43. 46 MetitieriT,ZanettiO,GeroldiC,etal.Realityorientationtherapytodelay
23 Ferna´ndez-BallesterosR,Zamarro´nMD,Ta´rragaL.Learningpotential:anew outcomesofprogressioninpatientswithdementia.Aretrospectivestudy.Clin
methodforassessingcognitiveimpairment.IntPsychogeriatr Rehab2001;15:471–8.
2005;17:119–28. 47 QuayhagenMP,QuayhagenM,CorbeilRR,etal.Copingwithdementia:
24 BeckerJT,MintunMA,AlevaK,etal.Compensatoryreallocationofbrain evaluationoffournonpharmacologicinterventions.IntPsychogeriatr
resourcessupportingverbalepisodicmemoryinAlzheimer’sdisease. 2000;12:249–65.
Neurology1996;46:692–700. 48 LoewensteinDA,AcevedoA,CzajaSJ,etal.Cognitiverehabilitationofmildly
25 HerbsterAN,NicholsT,WisemanMB,etal.Functionalconnectivityin impairedAlzheimerdiseasepatientsoncholinesteraseinhibitors.AmJGeriatr
auditoryverbalshort-termmemoryinAlzheimer’sdisease.Neuroimage Psychiatr2004;12:395–402.
1996;4:67–77. 49 HeissW-D,KesslerJ,MielkeR,etal.Long-termeffectsofphosphatidylserine,
26 DekoskyST,ScheffSW.SynapselossinfrontalcortexbiopsiesinAlzheimer’s pyritinolandcognitivetraininginAlzheimer’sdisease.Aneuropsychological,
disease:correlationwithcognitiveseverity.AnnNeurol1990;27:457–64. EEG,andPETinvestigation.Dementia1994;5:88–98.
www.jnnp.com
